DOI: 10.3389/fmed.2023.1213889; PMCID: PMC10600400
Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN) is a predominantly drug-induced disease, with a mortality rate of 15-20%, that engages the expertise of multiple disciplines: dermatology, allergy, immunology, clinical pharmacology, burn surgery, ophthalmology, urogynecology, and psychiatry. SJS/TEN has an incidence of 1-5/million persons per year in the United States, with even higher rates globally. One of the challenges of SJS/TEN has been developing the research infrastructure and coordination to answer questions capable of transforming clinical care and leading to improved patient outcomes. SJS/TEN 2021, the third research meeting of its kind, was held as a virtual meeting on August 28-29, 2021. The meeting brought together 428 international scientists, in addition to a community of 140 SJS/TEN survivors and family members. The goal of the meeting was to brainstorm strategies to support the continued growth of an international SJS/TEN research network, bridging science and the community. The community workshop section of the meeting focused on eight primary themes: mental health, eye care, SJS/TEN in children, non-drug induced SJS/TEN, long-term health complications, new advances in mechanisms and basic science, managing long-term scarring, considerations for skin of color, and COVID-19 vaccines. The meeting featured several important updates and identified areas of unmet research and clinical need that will be highlighted in this white paper.
Front Med (Lausanne)
HLA genotyping; SCORTEN; Stevens-Johnson Syndrome; Toxic Epidermal Necrolysis; body surface area; electronic medical record; pharmacogenomics; severe adverse cutaneous drug reactions
Marks ME, Botta RK, Abe R, et al. Updates in SJS/TEN: collaboration, innovation, and community. Front Med (Lausanne). 2023;10:1213889. Published 2023 Oct 11. doi:10.3389/fmed.2023.1213889